Market Update (NYSE:MRK): Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA

[Business Wire] – Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated relebactam , the company’s investigational beta-lactamase inhibitor, as . . . → Read More: Market Update (NYSE:MRK): Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA Similar Articles: Company Update (NYSE:MRK): Merck Announces Third-Quarter 2014 Dividend Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Hold Investor Briefing at Boston Research Facility Company Update (NYSE:MRK): Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29